Swiss Biotech Day: Molecular Partners' CEO and Swiss Biotech Association president Patrick Amstutz shares his take on biotech and previews what to expect from his U.S. listed company in 2025
May 5, 2025
1 min read
He describes the clinical multi-specific T-cell engager program that will have data this year, and highlights the idea behind a next-generation logic-gating platform. Plus, entering the clinic with a DLL3 radio-DARPin and choosing mesothelin as a second target.
.png){kind=logo}